Express Feedlot (Canada)

Company: Boehringer Ingelheim Animal Health

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza 3-Respiratory Syncytial Virus Vaccine

Modified Live Virus

BEEF & DAIRY

Express Feedlot Indications

This product has been shown to be effective for the vaccination of healthy cattle, including pregnant cows, against respiratory disease due to infectious bovine rhinotracheitis (IBR), bovine virus diarrhea types 1 and 2 (BVD1 & BVD2), parainfluenza 3 (PI3), and bovine respiratory syncytial virus (BRSV). This product was licensed prior to the requirement to establish a minimum age for use. The duration of immunity against IBR-induced abortion is at least 12 months. The duration for the remaining organisms has not been determined. For more information regarding efficacy and safety data go to productdata.aphis.usda.gov.

This vaccine may be used in pregnant cows or calves nursing pregnant cows, provided the cows were vaccinated pre-breeding according to label instructions with any Express^® FP vaccine.

Composition

The amber glass vial contains IBR, BVD1 (Singer 1a cytopathic), BVD2 (296 cytopathic), PI3, and BRSV modified live viruses (MLV). The plastic vial contains an adjuvant system. Neomycin and thimerosal added as preservatives.

Directions and dosage: Mix the accompanying bottle of diluent. Rehydrate the vaccine by aseptically adding the diluent to the vaccine vial. Mix the rehydrated vaccine and use immediately. Using aseptic technique, inject 2 mL subcutaneously in front of the shoulder and midway of the neck, away from the suprascapular lymph node. If initial vaccination, repeat with any Express^® vaccine containing BRSV MLV in 14 to 28 days. Contact your veterinarian or the manufacturer for information on revaccination frequency.

Fetal health risks associated with vaccination of pregnant animals with this vaccine cannot be unequivocally determined by clinical trials conducted for licensure. Appropriate strategies to address the risks associated with vaccine use in pregnant animals should be discussed with a veterinarian.

No vaccine can be expected to have 100% efficacy under all conditions. A small number of calves persistently infected with BVD may have a devastating effect on herd health.

Note: It is possible that healthy-appearing cattle can be persistently infected with or incubating virulent BVD virus at the time of vaccination. In view of these findings and suggested causes, BVD vaccine is contraindicated in persistently infected cattle and use should be limited only to healthy, immunocompetent, unstressed cattle.

Precautions

Store out of direct sunlight at 2-8°C. Do not freeze. Do not mix with other products, except as specified on the label. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Injection site swelling may occur. Stressed cattle should not be vaccinated. In case of anaphylactoid reaction, administer epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal.

For use in animals only.

EXPRESS^® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., St. Joseph, MO 64506

Tel.: 1 (888) 637-4251

VLN/PCN 124/1181.21

Distributed by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

CPN: 1182216.0